Clinical Trials
50 trialsAcalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure
AstraZeneca
SPiReL
Sunnybrook Health Sciences Centre
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
Curis, Inc.
ESCALADE
Acerta Pharma BV
ACCESS
Center for International Blood and Marrow Transplant Research
OPTIMIZE
Center for International Blood and Marrow Transplant Research
Study of CD30 CAR for Relapsed/Refractory CD30+ HL and CD30+ NHL
UNC Lineberger Comprehensive Cancer Center
Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL
UNC Lineberger Comprehensive Cancer Center
Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma
UNC Lineberger Comprehensive Cancer Center
ARQ 531-101
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Administration of T Lymphocytes for Prevention of Relapse of Lymphomas
UNC Lineberger Comprehensive Cancer Center
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
Novartis
A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (TRANSCEND-OUTREACH-007)
Juno Therapeutics, a Subsidiary of Celgene
BV-CHEP Chemotherapy for Adult T-cell Leukemia or Lymphoma
UNC Lineberger Comprehensive Cancer Center
Sepantronium Bromide for the Treatment of High-grade B-cell Lymphoma
Cothera Bioscience, Inc
Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's Lymphomas
Zhejiang DTRM Biopharma
A Clinical Study of ONCT-808 in Subjects With Relapsed or Refractory B-Cell Malignancies
Oncternal Therapeutics, Inc
ISRT 20 Gy for Indolent Localized Gastrointestinal (GI)-Lymphoma
University Hospital Muenster
A Study to Evaluate the Safety and Efficacy of JCAR017 in Pediatric Subjects With Relapsed/Refractory (r/r) B-cell Acute Lymphoblastic Leukemia (B-ALL) and B-cell Non-Hodgkin Lymphoma (B-NHL)
Celgene
GNR-084 Safety and Pharmacological Characteristics in Refractory or Relapse B-cell Precursor ALL
AO GENERIUM
Study of Betalutin for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma (LYMRIT-37-05)
Nordic Nanovector
FUSION NHL 001
Celgene
A Study of Zilovertamab and Ibrutinib in Patients With Relapsed or Refractory Mantle Cell Lymphoma
Oncternal Therapeutics, Inc
A Study of Ponatinib in Japanese Participants With Chronic Myeloid Leukemia (CML) and Ph+ Acute Lymphoblastic Leukemia (ALL)
Takeda
SOLAR
miRagen Therapeutics, Inc.
Study Evaluating Venetoclax in Subjects With Hematological Malignancies
AbbVie
FIL-BBV
Fondazione Italiana Linfomi - ETS
A Study of Brentuximab Vedotin in Participants With Relapsed or Refractory Hodgkin Lymphoma
Takeda
PRISM
miRagen Therapeutics, Inc.
BLAST
Amgen Research (Munich) GmbH
Treatment Study of Denintuzumab Mafodotin (SGN-CD19A) Plus RICE Versus RICE Alone for Diffuse Large B-Cell Lymphoma
Seagen Inc.
Denintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in Diffuse Large B-Cell Lymphoma or Follicular Lymphoma
Seagen Inc.
Dosimetry Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma (LYMRIT-37-02)
Nordic Nanovector
E7777 for the Treatment of Patients With Peripheral T-Cell Lymphoma
Eisai Inc.
SPINOZA
City of Hope Medical Center
Chidamide Combined With R-GDP in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Fudan University
Sharing Our Strength: A Research Study for Bone Marrow/Stem Cell Transplant Survivors
University of North Carolina, Chapel Hill
Clinical Study With Blinatumomab in Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)
Amgen Research (Munich) GmbH
Study of the BiTE® Blinatumomab (MT103) in Adult Patients With Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (ALL)
Amgen Research (Munich) GmbH
Clinical Study With Blinatumomab in Pediatric and Adolescent Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia
Amgen Research (Munich) GmbH
Clinical Study With Blinatumomab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Amgen Research (Munich) GmbH
Study of RAD001 in Patients With Relapsed/Refractory Hodgkin Lymphoma That Has Progressed After High-dose Chemotherapy and Autologous Stem Cell Transplant and/or After Gemcitabine- or Vinorelbine- or Vinblastine-based Treatment.
Novartis
A Randomized Phase IIb Placebo-Controlled Study of R-ICE Chemotherapy With and Without SGN-40 for Patients With DLBCL
Seagen Inc.
Study of SGN-40 in Patients With Relapsed Diffuse Large B-Cell Lymphoma
Seagen Inc.
A Safety Study of SGN-40 in Patients With Non-Hodgkin's Lymphoma
Seagen Inc.
A Safety Study in Patients With Chronic Lymphocytic Leukemia
Seagen Inc.
Trial to Define the Safety and Tolerability of SGN-40, Rituximab, and Gemcitabine in Patients With DLBCL
Seagen Inc.
Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)
Ariad Pharmaceuticals
SGN-30 and Combination Chemotherapy in Treating Patients With Newly Diagnosed Anaplastic Large Cell Lymphoma
National Cancer Institute (NCI)
P05538
AVEO Pharmaceuticals, Inc.